Detalhe da pesquisa
1.
Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer.
Clin Pharmacol Ther
; 115(3): 468-477, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37776107
2.
Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer.
Lung Cancer
; 175: 112-120, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495784
3.
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.
Clin Cancer Res
; 29(18): 3592-3602, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37491846
4.
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.
Leuk Res
; 134: 107390, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37776843
5.
Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
Adv Ther
; 39(10): 4757-4771, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35962934
6.
Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies.
JTO Clin Res Rep
; 2(10): 100224, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34647107